Letaplimab represents a novel therapeutic method for addressing complement-mediated illnesses. This monoclonal antibody targets complement component C1q, a key molecule of the complement cascade, potentially inhibit https://alyshaffoc711737.aboutyoublog.com/52729372/letaplimab-a-groundbreaking-therapeutic-strategy